Targeted hormone replacement therapy with the melanocortin-4 receptor agonist, setmelanotide, has been shown to be very effective in children with monogenetic obesity such as Bardet-Biedl syndrome (123). This evidence concerns the gene MC4R and Bardet-Biedl syndrome.